Since the increased GSK3β-mediated CREB S133 phosphorylation participates in ictogenesis in human patients and animal models of epilepsy [32,35,36], these findings indicate that AMPAR antagonists may negatively regulate surface GRIA expression via GSK3β/CREB signaling pathway in responders. Here, GSK3B is linked to epilepsy.